Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
June 02, 2023 07:00 ET
|
Autolus Therapeutics plc
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
May 12, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
May 04, 2023 07:00 ET
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License...
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
April 27, 2023 07:01 ET
|
Autolus Therapeutics plc
LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
April 27, 2023 07:00 ET
|
Autolus Therapeutics plc
Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapiesInnovative Depot Model intended to reduce delivery time by allowing for transit...
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
April 26, 2023 16:01 ET
|
Autolus Therapeutics plc
LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
April 26, 2023 07:06 ET
|
Autolus Therapeutics plc
- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...
Autolus Therapeutics to Host Virtual Capital Markets Day
April 25, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a...
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
April 20, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication in Molecular Therapy
April 04, 2023 07:00 ET
|
Autolus Therapeutics plc
- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR - AUTO1/22 may reduce CD19 negative escape in children with B-ALL, and may have broader applications in...